60 Degrees announced that the U.S. Food and Drug Administration has communicated its intention to send any comments regarding the Company’s babesiosis trial within the month of April, 2024, rather than March, 2024 as anticipated by the Company. The protocol submission mechanism as directed by the FDA, i.e., under the Company’s existing Investigational New Drug application, technically does not require a response from the FDA within a specified time frame. The Company is continuing preparations for a June 1, 2024 start date as previously communicated. Tafenoquine is the active ingredient in an anti-malarial approved by the FDA in 2018 and is indicated for the prophylaxis of malaria in patients aged 18 years of age and older
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SXTP:
- 60 Degrees Pharmaceuticals Embarks on Tafenoquine Research Partnership
- 60 Degrees Pharmaceuticals to sponsor pre-clinical studies of Tafenoquine use
- 60 Degrees Pharmaceuticals appoints Kristen Landon as CCO
- 60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
- 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
